International Journal of Medical Research & Health Sciences (IJMRHS)
ISSN: 2319-5886 Indexed in: ESCI (Thomson Reuters)
Reem S. Tashkandi
Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaPublications
-
Research
The Hazard of Developing Adverse Reactions in Rheumatoid Arthritis Patients receiving Intravenous Biologics: A Survival Analysis
Author(s): Haya M. Almalag*, Shiekha S. AlAujan, Hadeel Alkofide, Hawazin S. Alhazzani, Lamia A. Alzamel, Reem S. Tashkandi, Hussain F. Alarfaj, Abdurhman S. Alarfaj, Hanan H. Abouzaid, Ali M. Alhadri and Mohammed A. Omair
Objectives: Limited previous studies have investigated the hazard and time to develop Adverse Drug Reactions (ADRs) of Intravenous (IV) biological Disease-Modifying Antirheumatic Drugs (bDMARDs) in patients with Rheumatoid Arthritis (RA). This study aimed to investigate the hazard of using different IV originator bDMARDs in comparison to each other and to assess the survival of this hazard in RA patients with or without conventional synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs). Methods: This is a single-centre retrospective cohort study at in Saudi Arabia, of adult RA patients receiving IV originator bDMARDs, including Tocilizumab (TCZ), Rituximab (RTX), Abatacept (ABA), and Infliximab (IFX), with or without conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs). Data extraction was between January 2019 to March 2020. T.. Read More»
Select your language of interest to view the total content in your interested language